Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

NCT00526799 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Study closed to accrual due unfavorable interim analysis

Conditions

Ovarian Cancer

Interventions

DRUG: Sorafenib
DRUG: Topotecan

Sponsor

Daniela Matei, MD

Collaborators

[object Object]
[object Object]